Patient undergoing cardiovascular check-up. The risk of death from any cause was higher with degarelix. Degarelix did not reduce the risk of major adverse cardiovascular events (MACE) when compared ...
FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
FDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer. The Food and Drug Administration approved Mozobil (plerixafor) in December for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results